Lakin Sullivan
Family · Laurel, MSNPI 1215685664
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 225 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,538 and has fallen 87.2% since, to $197 in 2025. Among family clinicians in MS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$761
- Pfizer$576
- SK Life Science, Inc.$538
- Acadia Pharmaceuticals Inc$254
- Eisai Inc.$217
- Otsuka America Pharmaceutical, Inc.$124
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,009100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $761 |
| Pfizer | 34 | $576 |
| SK Life Science, Inc. | 23 | $538 |
| Acadia Pharmaceuticals Inc | 12 | $254 |
| Eisai Inc. | 11 | $217 |
| Otsuka America Pharmaceutical, Inc. | 6 | $124 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $122 |
| Lundbeck LLC | 8 | $119 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $103 |
| Lilly USA, LLC | 7 | $101 |
| Sanofi | 5 | $99 |
| Upsher-smith Laboratories LLC | 5 | $92 |
| Teva Pharmaceuticals USA, Inc. | 5 | $81 |
| Sumitomo Pharma America, Inc. | 4 | $69 |
| Genentech USA, Inc. | 4 | $67 |
| Amgen | 4 | $66 |
| Johnson & Johnson | 4 | $62 |
| Corium, LLC | 4 | $62 |
| Inspire Medical Systems, Inc. | 3 | $59 |
| Argenx US, Inc. | 3 | $54 |
| Novartis | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| UCB, Inc. | 2 | $37 |
| Biogen | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Valinor Pharma, LLC | 2 | $32 |
| Neurelis, Inc. | 1 | $26 |
| Harmony Biosciences LLC | 1 | $20 |
| Catalyst Pharmaceuticals, Inc. | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
How this compares
$4,009 in reported general payments places this provider in the 90th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VimpatLacosamide | 13 | $29,140 |
| Nurtec OdtRimegepant Sulfate | 12 | $19,216 |
| AptiomEslicarbazepine Acetate | 14 | $18,559 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 694 | $11,992 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 501 | $11,447 |
| MovantikNaloxegol Oxalate | 13 | $8,359 |
| Emgality PenGalcanezumab-Gnlm | 11 | $8,100 |
| TrintellixVortioxetine Hydrobromide | 15 | $7,167 |
| LinzessLinaclotide | 12 | $6,161 |
| Diclofenac Sodium | 190 | $2,701 |
| Oxycodone Hcl | 154 | $2,507 |
| Gabapentin | 384 | $2,211 |
| Duloxetine Hcl | 246 | $2,053 |
| Levetiracetam | 68 | $1,561 |
| Carbamazepine | 44 | $1,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Vimpat | $37 | $29,14013 claims |
| PfizerNurtec Odt | $576 | $19,21612 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $34 | $18,55914 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $38 | $7,16715 claims |
| AbbVieLinzess | $761 | $6,16112 claims |
| Upsher-smith Laboratories LLCTopiramate | $92 | $58685 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,007 family providers in Mississippi.
Other family in Laurel
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
- Andrea WallaceOlive Branch$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.